Dabaja BS, Hoppe BS, Plastaras JP, et al. Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines

Autor: Bradford S. Hoppe, John P. Plastaras, Bouthaina S. Dabaja

Publikováno v: Blood. 133(12)

Among adult lymphoma survivors, radiation treatment techniques that increase the excess radiation dose to organs at risk (OARs) put patients at risk for increased side effects, especially late toxicities. Minimizing radiation to OARs in adults patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a40934401fe858856e9daec0275ce27b
https://pubmed.ncbi.nlm.nih.gov/30108066

Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organs.

Autor: Manzar GS; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Cha EE; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Corrigan KL; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Yoder AK; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Schrank BR; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Nasr LF; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Chihara D; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Castillo LM; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Nair R; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Jain P; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Neelapu SS; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Rodriguez MA; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Strati P; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Nastoupil LJ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Gunther JR; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Dabaja BS; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Pinnix CC; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Wu SY; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Fang PQ; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Publikováno v: Frontiers in oncology [Front Oncol] 2024 Sep 11; Vol. 14, pp. 1447020. Date of Electronic Publication: 2024 Sep 11 (Print Publication: 2024).

MALT Lymphoma of the Urinary Bladder Shows a Dramatic Female Predominance, Uneven Geographic Distribution, and Possible Infectious Etiology

Autor: Lyapichev KA, Ivashkevich Y, Chernov Y, Chinenov D, Shpot E, Bessonov AA, Dabaja BS, Konoplev S

Publikováno v: Research and Reports in Urology, Vol Volume 13, Pp 49-62 (2021)

Kirill A Lyapichev,1,* Yana Ivashkevich,1,* Yaroslav Chernov,2 Denis Chinenov,2 Evgeniy Shpot,2 Alexander A Bessonov,3 Bouthaina S Dabaja,4 Sergej Konoplev1 1Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, T

Externí odkaz: https://doaj.org/article/d4f59eb3871041058b688254a2ea8146

Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial.

Autor: Gunther JR; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: jgunther@mdanderson.org., Xu J; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bhutani MS; Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Strati P; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fang PQ; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wu SY; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dabaja BS; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dong W; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bhosale PR; Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Flowers CR; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nair R; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Malpica Castillo L; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fayad L; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Iyer SP; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Parmer S; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang M; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lee HJ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Samaniego F; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Westin J; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ahmed S; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nze CC; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jain P; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Neelapu SS; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Rodriguez MA; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chihara D; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nastoupil LJ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pinnix CC; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Publikováno v: The Lancet. Haematology [Lancet Haematol] 2024 Jul; Vol. 11 (7), pp. e521-e529. Date of Electronic Publication: 2024 Jun 03.

Management and Outcomes of Patients with Refractory Solitary Plasmacytoma after Treatment with Definitive Radiation Therapy.

Autor: Fang P; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: pfang@mdanderson.org., Pinnix CC; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wu SY; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lee HC; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Patel KK; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Saini N; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Becnel MR; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kaufman G; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Thomas SK; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Orlowski RZ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Amini B; Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lin P; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Dabaja BS; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Gunther JR; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Publikováno v: International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2024 May 01; Vol. 119 (1), pp. 193-199. Date of Electronic Publication: 2023 Dec 08.